Filter by content type
Filter by year
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
April 21, 2021 - … Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer … Research … Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell …
Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 16, 2021 - … Vaccinex announced the publication of results from the CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell lung cancer … Vaccinex announced the publication of results from the CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell …
Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 17, 2021 - … head and neck cancer Announced publication of results from CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell lung cancer … Announced the publication of results from the CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell …
Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
June 8, 2021 - … treatment benefit to patients with non-small cell lung cancer. We are pleased to have now initiated this new … treatment benefit to patients with non-small cell lung cancer. We are pleased to have now initiated this new … treatment benefit to patients with non-small cell lung cancer. We are pleased to have now initiated this new …